| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epidemiology and Outcomes |
* Division of Nephrology, Queen's University, and Clinical Research Centre, Kingston General Hospital, Kingston, Ontario, Canada
Correspondence: Dr. Rachel M. Holden, 3048 C Etherington Hall, Queen's University, Kingston, Ontario, Canada, K7L 2V6. Phone: 613-533-3134; Fax: 613-533-2923; E-mail: holdenr{at}kgh.kari.net
Background and objectives: Few studies have examined risk factors for hemorrhage in hemodialysis patients. The contribution of warfarin and antiplatelet agent exposure to the incidence of first major bleeding episodes in hemodialysis patients was determined.
Design, setting, participants, & measurements: Retrospective chart review was performed in eligible hemodialysis patients. Incidence rates were determined as the number of first major bleeding events divided by the total exposure time on each treatment combination. Time-dependent covariates and Cox proportional hazard models were used to determine the hazard rate of having a first major bleeding event.
Results: A total of 1028 person-years of exposure were observed from 255 patients with a median follow-up time of 3.6 yr. The incidence rate of major bleeding episodes was 2.5% per person-year. The incidence of major bleeding episodes was 3.1% per person-year of warfarin exposure, 4.4% per person-year of aspirin exposure, and 6.3% per person-year of exposure to the combination of warfarin and aspirin. Compared with patients who were not prescribed warfarin or aspirin, the multivariable hazard ratio for time to first major bleeding event was 3.59 for warfarin, 5.24 for aspirin, and 6.19 for the combination of aspirin and warfarin.
Conclusions: The risk for major bleeding episodes in hemodialysis patients increases significantly while on aspirin and/or warfarin, although warfarin alone did not reach statistical significance. Future studies should evaluate the efficacy of these agents in the secondary prevention of cardiovascular events in this high-risk population.
This article has been cited by other articles:
|
|
 |
|
  M. M. Sood, P. Komenda, A. R. Sood, C. Rigatto, and J. Bueti The Intersection of Risk and Benefit: Is Warfarin Anticoagulation Suitable for Atrial Fibrillation in Patients on Hemodialysis? Chest, October 1, 2009; 136(4): 1128 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Sood, C. Rigatto, J. Bueti, C. Lang, L. Miller, A. PonnamPalam, M. Reslerova, A. Sood, and P. Komenda Thrice weekly warfarin administration in haemodialysis patients Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3162 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hiremath, R. M. Holden, D. Fergusson, and D. L. Zimmerman Antiplatelet Medications in Hemodialysis Patients: A Systematic Review of Bleeding Rates Clin. J. Am. Soc. Nephrol., August 1, 2009; 4(8): 1347 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Chan, J. M. Lazarus, R. Thadhani, and R. M. Hakim Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients J. Am. Soc. Nephrol., April 1, 2009; 20(4): 872 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. CHIRAS, E. D. PAPADAKIS, A. KATOPODI, E. CHATZIANESTI, K. FOURTOUNAS, S. PAPAKONSTANTINOU, I. THEODOROPOULOS, A. DAKOURAS, N. ZEREFOS, D. VALIS, et al. Platelet GP IIIA Polymorphism HPA-1 (PLA1/2) Is Associated with Hypertension as the Primary Cause for End-stage Renal Disease in Hemodialysis Patients from Greece In Vivo, January 1, 2009; 23(1): 177 - 181. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
